Pharmafile Logo
Pharmafocus logo
Advanced Search

Catalent acquires current minority interest in R.P. Scherer, Eberbach, Germany

January 31, 2012
Manufacturing and Production

SOMERSET, NJ, January 30, 2012 – Catalent Pharma Solutions, a leading global drug delivery technology company, today announced the signing …

News
Press release
Ranbaxy picture

Ranbaxy taken to task by FDA over manufacturing woes

January 31, 2012
Manufacturing and Production FDA, Ranbaxy, manufacturing, woes

Indian pharma company Ranbaxy will be banned from manufacturing drugs at certain plants for the US market until it corrects …

News

GMP issues affect Mircera, Xenical production at Roche plant

January 31, 2012
Manufacturing and Production GMP, Mircera, Roche, Tamiflu, Xenical

Supply of two Roche products has been disrupted after an active pharmaceutical ingredient (API) production facility in the US was …

News

Abbott slashes 700 jobs

January 31, 2012
Manufacturing and Production, Sales and Marketing Abbott, FDA, manufacturing

Abbott Laboratories has said it will cut 700 jobs across its US and Puerto Rican operations, including hundreds of manufacturing …

News

Pharma manufacturing news in brief

January 31, 2012
Manufacturing and Production Aptar Pharma, Granules-Omnichem, Lpath, Pii, Shemberg

Facility updates from Aptar Pharma, Granules-Omnichem and Pii, plus a fill/finish problem for Lpath and seaweed-based pharma capsules. Aptar Pharma …

News

Dietmar Leitner joins Napp Pharmaceuticals as its new managing director

January 31, 2012
Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Dietmar Leitner, Napp Pharmaceuticals

Dietmar Leitner has been appointed managing director of Napp Pharmaceuticals, part of the Napp Pharmaceutical Group.   Dietmar has worked …

Appointment
Roche picture

Roche’s Erivedge gains FDA approval

January 31, 2012
Sales and Marketing Erivedge, FDA, Roche

The FDA has approved Roche’s Erivedge to treat patients with a common form of skin cancer. Erivedge (vismodegib) is now …

News

Misinformation charges against Servier dropped

January 30, 2012
Sales and Marketing European Commission, Servier, anti-competitive behaviour

The European Commission has dropped a case against Servier in which the French manufacturer was accused of providing misleading information.The …

News

Pfizer in talks on Sandwich site sale

January 30, 2012
Research and Development Pfizer, Sandwich

Pfizer has begun talks with a real estate investor to sell its R&D centre in Sandwich. The site was Pfizer’s …

News

PM Society celebrates new-look advertising awards

January 30, 2012
Medical Communications, Sales and Marketing Creative Lynx, Daaichi Sankyo, PM Society Awards, Torre Lazur McCann

The PM Society has held its annual healthcare advertising awards, which this year saw some significant changes to award categories. …

News

FDA approves Pfizer cancer drug Inlyta

January 30, 2012
Sales and Marketing Nexavar, Pfizer, Sutent, rcc, renal cell carcinoma

Pfizer’s kidney cancer drug Inlyta has gained US approval for second line treatment for the disease. Inlyta (axitinib) is now …

News

Government bites back against NHS reform naysayers

January 27, 2012
Sales and Marketing BMJ, Lansley, NHS, reforms

The UK government has come out against healthcare groups that are opposing its plans to radically reform the NHS.  Speaking …

News

Medical Research Network starts major global expansion programme

January 27, 2012
Business Services

Leading unique Clinical Trial Support Organisation (CTSO), Medical Research Network (MRN), has completed the first stage of a major global …

News
Press release

James Murdoch steps down from GSK board

January 27, 2012
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing GSK, James Murdoch

GlaxoSmithKline has announced that after nine years with the firm, Sir Crispin Davis, Sir Robert Wilson and Larry Culp will …

Appointment
Boehringer picture

Boehringer broadens afatinib studies

January 27, 2012
Research and Development, Sales and Marketing Boehringer Ingelheim, Cancer, afatinib

Boehringer Ingelheim is expanding the scope of its studies into afatinib to test its use against head and neck cancers. …

News
Amgen picture

Amgen buys Micromet for $1.2 billion

January 27, 2012
Research and Development, Sales and Marketing Amgen. Micromet, blinatumomab

Amgen is to buy German biotech firm Micromet for $1.16 billion to broaden its mid-stage pipeline and consolidate its oncology …

News

AXON Communications appoints Tina Hahn as vice president

January 27, 2012
Medical Communications AXON Communications, Tina Hahn

AXON Communications has announced the appointment of Dr Tina Hahn as vice president, based in Copenhagen, Denmark. In addition to …

Appointment

Bristol-Myers Squibb elects Gerald Storch to board of directors

January 26, 2012
Business Services, Manufacturing and Production, Research and Development, Sales and Marketing BMS, Gerald Storch

Bristol-Myers Squibb has announced that its board has elected Gerald Storch to serve as a member of the audit committee, …

Appointment
Abbott image

Abbott strong as it prepares for spin-out

January 26, 2012
Sales and Marketing Abbott, GAAP, Humira

Abbott enjoyed a strong 2011 thanks to Humira and emerging market growth, with overall worldwide sales rising by 4.1 per …

News
Rebif image

Rebif approved for early use in MS

January 26, 2012
Sales and Marketing MS, Merck KGaA, Merck Serono, Rebif

The European Commission has approved an indication for multiple sclerosis treatment Rebif that treats early signs of the condition.This EC …

News
The Gateway to Local Adoption Series

Latest content

MRM Health’s ulcerative colitis treatment receives FDA Investigational New Drug clearance

January 27, 2026

Crystalys Therapeutics appoints Justin Thacker as Chief Financial Officer

January 27, 2026

Rentschler Biopharma appoints Uwe Buecheler as interim CEO

January 26, 2026

Sandoz’ Ondibta receives European Commission approval for diabetes

January 26, 2026

Complement Therapeutics’ geographic atrophy treatment receives FDA Fast Track designation

January 22, 2026